Economic Impact of Ramipril on Hospitalization of High-Risk Cardiovascular           Patients

Carroll, Cathryn A.; Coen, Michael M; Piepho, Robert W.

doi:10.1345/aph.1c125

Cited by 10 publications

(5 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We excluded duplicate papers (n = 465), papers not published in English (n = 248), papers in which CHF was not the subject of interest (n = 2455) and papers that did not describe decisionanalytic models as defined previously (n = 2538). Several studies were subsequently excluded as their study population was not exclusively CHF patients, [9,10] looked only at patients in acute heart failure, [11][12][13][14] evaluated clinical trials only economically or did not describe the extrapolation method used. [15][16][17][18] Five additional studies were identified through a hand search.…”

Section: Resultsmentioning

confidence: 99%

Decision-Analytic Models to Simulate Health Outcomes and Costs in Heart Failure

et al. 2011

View full text Add to dashboard Cite

Chronic heart failure (CHF) is a critical public health issue with increasing effect on the healthcare budgets of developed countries. Various decision-analytic modelling approaches exist to estimate the cost effectiveness of health technologies for CHF. We sought to systematically identify these models and describe their structures. We performed a systematic literature review in MEDLINE/PreMEDLINE, EMBASE, EconLit and the Cost-Effectiveness Analysis Registry using a combination of search terms for CHF and decision-analytic models. The inclusion criterion required 'use of a mathematical model evaluating both costs and health consequences for CHF management strategies'. Studies that were only economic evaluations alongside a clinical trial or that were purely descriptive studies were excluded. We identified 34 modelling studies investigating different interventions including screening (n = 1), diagnostics (n = 1), pharmaceuticals (n = 15), devices (n = 13), disease management programmes (n = 3) and cardiac transplantation (n = 1) in CHF. The identified models primarily focused on middle-aged to elderly patients with stable but progressed heart failure with systolic left ventricular dysfunction. Modelling approaches varied substantially and included 27 Markov models, three discrete-event simulation models and four mathematical equation sets models; 19 studies reported QALYs. Three models were externally validated. In addition to a detailed description of study characteristics, the model structure and output, the manuscript also contains a synthesis and critical appraisal for each of the modelling approaches. Well designed decision models are available for the evaluation of different CHF health technologies. Most models depend on New York Heart Association (NYHA) classes or number of hospitalizations as proxy for disease severity and progression. As the diagnostics and biomarkers evolve, there is the hope for better intermediate endpoints for modelling disease progression as those that are currently in use all have limitations.

show abstract

Section: Resultsmentioning

confidence: 99%

Decision-Analytic Models to Simulate Health Outcomes and Costs in Heart Failure

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Считается, что экономическая эффективность рамиприла у лиц, имеющих средний риск развития осложнений ССЗ, сопоставима с таковой статинов [44]. Результаты еще одного анализа [45], основанного на данных о применении рамиприла в течение 4 лет у 9 тыс. больных с высоким риском развития ССО, но ФВ ЛЖ >40%, свидетельствовали о снижении общих расходов на лечение за счет терапии, которое достигало $871 тыс.…”

Section: место рамиприла у пациентов с агunclassified

Modern antihypertensive therapy: the effectiveness of a unique Russian fixed-dose combination of ramipril and indapamide

Конради

Nedogoda²,

Недошивин³

et al. 2020

Russ J Cardiol

View full text Add to dashboard Cite

show abstract

“…the european Society of hypertension and the european Society of cardiology stated in their guidelines that all antihypertensive therapies can be considered as first-line choice drugs (34). Accordingly, the costs of antihypertensive pharmacotherapy and cVD complications have become extremely important (6). cVDs can pose a great burden on any healthcare system.…”

Section: Introductionmentioning

confidence: 99%

The Cost-Effectiveness of Hypertension Pharmacotherapy in Serbia: A Markov Model

Lakic

Petrova

Bogavac-Stanojević

et al. 2012

Biotechnology & Biotechnological Equipment

View full text Add to dashboard Cite

Economic Impact of Ramipril on Hospitalization of High-Risk Cardiovascular Patients

Abstract: The results demonstrate that the use of ramipril provides cost-effective treatment for high-risk cardiovascular patients with an ejection fraction >40%.

Cited by 10 publications

References 15 publications

Decision-Analytic Models to Simulate Health Outcomes and Costs in Heart Failure

Decision-Analytic Models to Simulate Health Outcomes and Costs in Heart Failure

Modern antihypertensive therapy: the effectiveness of a unique Russian fixed-dose combination of ramipril and indapamide

The Cost-Effectiveness of Hypertension Pharmacotherapy in Serbia: A Markov Model

Contact Info

Product

Resources

About